Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Accumulated Other Comprehensive Income Loss?

  Alexion Pharmaceuticals Inc ( ALXN ) |
1995 - 2021 (27 years)

Accumulated Other Comprehensive Income Loss is 
-$479.6M (1Y +43.7% )

ALXN Stock Price & Accumulated Other Comprehensive Income Loss

Accumulated Other Comprehensive Income Loss for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Accumulated Other Comprehensive Income Loss

chevron_right 2021 -$125.0M +88.3x
( +18.1% / year avg)
chevron_left 1995 -$1.4M
vertical_align_top Peak $293.0M +1.73x *
vertical_align_bottom Bottom -$399.0M
arrow_drop_up # Up Years 14 14 of 27
years up.
arrow_drop_down # Down Years 13
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 1995 , or +0.51x the rate relative to it's accumulated other comprehensive income loss over the same period.
  • If ALXN grows it's stock at the same rate as it's accumulated other comprehensive income loss (+18.1%/year) , it's stock price will grow +527% and hit $573.86 over the next 10 years.
  • ALXN's stock price has gone up 0 of the 14 years (0%) it's accumulated other comprehensive income loss were also up.
* A modified method (see: here) is used to calculate changes that involve negative numbers.
  • ALXN Historical Accumulated Other Comprehensive Income Loss Table
    in $ million
    * A modified method (see: here) is used to calculate changes that involve negative numbers.
    Year Accumulated Other Comprehensive Income Loss YoY % Change* Stock Price YoY % Change (Stock Price)
    4/1/2021 $-125 -68.7% - -
    4/1/2020 $-399 191.2% - -
    4/1/2019 $-137 80.3% - -
    4/1/2018 $-76 -265.2% - -
    4/1/2017 $46 -75.1% - -
    4/1/2016 $185 -36.9% - -
    4/1/2015 $293 -1015.6% - -
    4/1/2014 $-32 -169.6% - -
    4/1/2013 $46 48.4% - -
    4/1/2012 $31 -170.5% - -
    4/1/2011 $-44 -276.0% - -
    4/1/2010 $25 -350.0% - -
    4/1/2009 $-10 125.5% - -
    4/1/2008 $-4 -91.6% - -
    4/1/2007 $-52 -2.6% - -
    4/1/2006 $-54 8.1% - -
    4/1/2005 $-49 -1.6% - -
    4/1/2004 $-50 12.6% - -
    4/1/2003 $-45 34.5% - -
    4/1/2002 $-33 36.1% - -
    4/1/2001 $-24 32.6% - -
    4/1/2000 $-18 41.9% - -
    4/1/1999 $-13 19.1% - -
    4/1/1998 $-11 17.0% - -
    4/1/1997 $-9 -63.3% - -
    4/1/1996 $-25 1728.6% - -
    4/1/1995 $-1 - - -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • Accumulated other comprehensive income (OCI) includes unrealized gains and losses reported in the equity section of the balance sheet that are netted below-retained earnings. Other comprehensive income can consist of gains and losses on certain types of investments, pension plans, and hedging transactions.

    For more detailed definitions, please see Investopedia.